Institut Gustave Roussy, Villejuif; Centre René Gauducheau, Nantes; and Centre Léon Bérard, Lyon, France.

Department of Oncology, Military Medical Institute; and Klinika Nowotworów Ukladu Moczowego, Warsaw, Poland; Universitätsklinikum Grosshadern, Munich; and Bayer Vital, Leverkusen, Germany; Baylor-Sammons/Texas Oncology, Dallas, TX; Evanston Northwestern Healthcare, Center on Outcomes Research and Education, Evanston, IL; Bayer HealthCare Pharmaceuticals, Montville, NJ; and Cleveland Clinic Cancer Center, Cleveland, OH.

An open-label, phase II study to evaluate progression-free survival (PFS), overall best response, adverse events (AEs), and patient-reported outcomes with sorafenib versus interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer.

A total of 189 patients were randomly assigned to oral sorafenib 400 mg twice daily or to subcutaneous IFN-alpha-2a 9 million U three times weekly (period 1). Sorafenib patients who progressed were dose-escalated to 600 mg twice daily; IFN-alpha-2a patients who progressed were switched to sorafenib 400 mg twice daily (period 2).

In period 1 PFS was similar for sorafenib-treated (n = 97; 5.7 months) and IFN-alpha-2a-treated patients (n = 92; 5.6 months); more sorafenib-treated patients had tumor shrinkage (68.2% v 39.0%). Common drug-related AEs (Grades >/= 3) for sorafenib were hand-foot skin reaction (11.3%), diarrhea (6.2%), and rash/desquamation (6.2%); for IFN-alpha-2a, these were fatigue (10.0%), nausea (3.3%), flu-like syndrome (2.2%), and anorexia (2.2%). Sorafenib-treated patients reported fewer symptoms, better quality of life (QOL), and greater treatment satisfaction. In period 2, 41.9% of patients who received sorafenib 600 mg twice daily (n = 43) experienced tumor reduction (median PFS, 3.6 months). After the switch to sorafenib 400 mg twice daily, tumors were reduced in 76.2% of 50 patients (median PFS, 5.3 months). AEs were mostly grade 1 to 2; no increase in AEs of grades >/= 3 occurred after sorafenib dose escalation.

In this study, sorafenib resulted in similar PFS as IFN-alpha-2a in patients with untreated RCC. However, sorafenib-treated patients experienced greater rates of tumor size reduction, better QOL, and improved tolerability. Both dose escalation of sorafenib after progression and a switch to sorafenib after progression on IFN-alpha-2a resulted in clinical benefit.

Written by:
Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM.   Are you the author?

Reference:
J Clin Oncol. 2009 Jan 26. Epub ahead of print.
doi:10.1200/JCO.2008.19.3342

PubMed Abstract
PMID:19171708

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!